Дапсон

Quick links to important sections

Дапсон

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Дапсон

Property Description
Active Ingredient Dapsone (diaminodiphenyl sulfone, DDS)
Form Oral Tablet; Topical Gel or Cream
Pharmacological Class Sulfone; Anti-infective Agent
General Purpose Combating infection and controlling inflammation
Origin Synthetic derivative

What Type of Medicine is Дапсон (Dapsone) and What is its Composition?

Дапсон (Dapsone) is a synthetic pharmaceutical agent and the foundational member of the sulfone chemical class, categorized as an anti-infective agent with antibiotic properties. The sole active ingredient is Dapsone itself, chemically known as diaminodiphenyl sulfone (DDS). The drug is a specialized, single-ingredient product designed to target certain bacterial and protozoal pathogens. Dapsone acts as a structural analog of p-aminobenzoic acid (PABA) to inhibit folate synthesis in susceptible organisms, impeding bacterial growth. While the INN is Dapsone, brands that feature this active ingredient include Aczone (often used topically) and Avlosulfon (typically used orally for systemic conditions).

In Which Forms is Dapsone Available, and What is its General Purpose?

Dapsone is available in two primary physical formats: the orally administered tablet for systemic treatment, and a topical gel or cream for localized application to the skin. This dual availability allows the medication to be delivered via two distinct routes of administration, addressing both widespread internal issues, such as infection prophylaxis in immunocompromised patients, and external skin manifestations. The medicine's general therapeutic purpose stems from its dual action, which provides both an antimicrobial effect by inhibiting bacterial growth and an anti-inflammatory action. Dapsone interferes with the function and adhesion of neutrophils, which are white blood cells that drive inflammation. This helps to contain infectious spread while reducing symptoms of tissue damage, such as swelling and irritation, which are features of the conditions the drug is utilized to manage.

Regulatory References

  1. NCI Drug Dictionary

What side effects are possible with Дапсон?

Possible Side Effects and Safety Information: Dapsone

The safety profile of Dapsone is formally documented by regulatory authorities, classifying potential adverse reactions by both frequency and the specific organ system affected. The most frequently cited safety concerns involve the Blood and Lymphatic System, as Dapsone is associated with dose-related effects, primarily haemolytic anaemia and methaemoglobinaemia, which are classified as common adverse reactions.


Serious Adverse Reactions and Systemic Concerns

Official labeling highlights the risk of rare, but clinically significant, serious adverse reactions. These include severe blood disorders such as agranulocytosis and aplastic anaemia. The most severe systemic concern is Dapsone Hypersensitivity Syndrome (DHS), a rare, multi-organ reaction that typically manifests three to six weeks after treatment initiation and can progress rapidly. Severe skin reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented.


Organ System and Population-Specific Notes

Adverse effects are also documented for other System-Organ Classes (SOCs). These include Nervous System effects, such as peripheral neuropathy, which is generally associated with prolonged exposure, and Hepatobiliary Disorders, including documented cases of jaundice and elevated liver enzymes.

Specific regulatory safety notes emphasize that individuals with Glucose-6-phosphate Dehydrogenase (G6PD) deficiency are more susceptible to severe haemolytic reactions from Dapsone. Therefore, testing for this condition is generally recommended by official guidelines. Caution and monitoring are also required in patients with pre-existing renal or hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Dapsone overdose is characterized by severe clinical manifestations linked to methemoglobinemia and hemolysis. Documented signs of overdosage requiring immediate attention include cyanosis (a bluish-gray discoloration of the skin and mucous membranes), hypoxia (low oxygen supply), seizures, vomiting, and altered mental status. These manifestations are the primary result of the drug's effect on red blood cells, which can lead to life-threatening outcomes if not promptly addressed.


Emergency Actions Mandated by Regulators

Regulatory documents mandate seeking immediate medical attention upon any suspicion of Dapsone overdosage, especially if signs like cyanosis or breathing difficulty are observed. Authorities instruct users to contact emergency services immediately if the affected individual has collapsed or experienced a seizure. The specific antidotal treatment for Dapsone-induced methemoglobinemia is documented as Methylene Blue (administered intravenously), though patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency cannot receive this treatment due to the risk of worsening hemolysis.


Monitoring and Follow-Up

Given Dapsone's long half-life, the official management plan requires close clinical and laboratory monitoring for an extended period. This is necessary to detect and manage the risk of rebound methemoglobinemia and delayed hemolytic anemia, which may require repeated antidotal doses or, in severe cases, a blood transfusion.

Therapeutic Uses of Дапсон

The medication is utilized in addressing two primary therapeutic areas: situations involving specific chronic infections and conditions presenting with severe, challenging inflammatory symptoms.

Dapsone is generally considered relevant in areas involving certain distressing symptoms linked to systemic or organ-specific functional stress. It is applied in addressing the bacterial cause of diseases like leprosy and is commonly used to help with prophylaxis against specific opportunistic infections, such as Pneumocystis pneumonia (PCP). The medication is considered relevant for conditions presenting with intense inflammation, including dermatitis herpetiformis, refractory chronic spontaneous urticaria, and severe inflammatory acne vulgaris.

This application provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. It is applied in clinical settings that involve acute or unstable symptom patterns, helping to ease challenging symptoms that interfere with daily functioning.

Quick Fact: Relief for Pruritus and Chronic Inflammation

Dapsone may assist with managing symptoms related to inflammatory or irritative states where groups of symptoms appear suddenly or fluctuate. It is relevant for easing severe, chronic itching (pruritus) and the development of disruptive skin lesions, supporting the patient during difficult episodes by easing distress.

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Contraindicated Populations Patients with known hypersensitivity to Dapsone or any drug component.
Individuals with severe anemia or a history of Dapsone-induced severe hemolysis or agranulocytosis.
Age-Related Eligibility Use of the topical gel is established for patients 9 years of age and older, defining an exclusion for children younger than 9.
Oral tablet dosage in children is weight-based for specific conditions; safety/efficacy is not established in all pediatric groups.
Condition-Specific Restrictions Caution is mandatory in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, methemoglobin reductase deficiency, hepatic impairment, or renal impairment.
Pregnancy and Lactation Status Pregnancy (Oral): Use is restricted to situations where the potential benefit justifies the potential fetal risk (Category C).
Lactation: Use is not recommended as Dapsone is excreted in breast milk and may cause hemolytic reactions in the nursing infant.

These official regulatory criteria define the boundaries of use by prohibiting Dapsone in populations with specific blood disorders or a history of severe drug reactions, while requiring conditional caution for individuals with certain metabolic or organ function deficiencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Dapsone documents specific interactions classified based on their effect on drug levels (pharmacokinetic) or the risk of adverse outcomes (pharmacodynamic).

Documented Exposure Modification

Interaction Type Interacting Agent Official Outcome
Decreased Exposure Rifampin (or Rifabutin) Reduces Dapsone plasma clearance, resulting in a 7 to 10-fold reduction in Dapsone levels.
Increased Exposure Probenecid Reduces Dapsone excretion, leading to increased Dapsone plasma concentrations.
Increased Exposure Trimethoprim/Sulfamethoxazole Increases the systemic exposure (AUC) of Dapsone and its active metabolite.

Pharmacodynamic and Restricted Combinations

Co-administration with other drugs that induce methemoglobinemia (e.g., Acetaminophen, Sulfonamides) results in an additive effect that increases the risk of elevated methemoglobin levels. The use of Dapsone is contraindicated with Saquinavir due to a documented risk of irregular heartbeat.

Timing and Substance Restrictions

The Oral Typhoid Vaccine must not be taken until at least three days after completing a course of Dapsone due to the risk of reduced vaccine effectiveness. The herbal product St. John's Wort is documented to potentially increase the formation of the hemolysis-associated metabolite, dapsone hydroxylamine. An important population-specific caution notes an increased likelihood of hemolysis in patients with G6PD Deficiency when Dapsone is combined with agents like Trimethoprim/Sulfamethoxazole.

Mechanism of Action

Competitive Inhibition of Microbial Metabolism

Dapsone exerts its anti-infective effect by acting as a competitive inhibitor of the bacterial enzyme Dihydropteroate Synthetase (DHPS). By mimicking the natural bacterial metabolite PABA, Dapsone binds to the DHPS active site, disrupting the synthesis of dihydrofolic acid. This molecular step prevents the organism from producing the necessary precursors for its DNA and RNA, resulting in the physiological effect of inhibited microbial proliferation. This mechanism supports the dampening of bacterial load and contributes to a reduced rate of organismal increase.


️ Modulation of Neutrophil-Driven Inflammation

The molecule possesses a distinct anti-inflammatory mechanism focused on regulating the function of host neutrophils, the immune cells central to acute inflammatory responses. Dapsone inhibits the enzyme Myeloperoxidase (MPO), thereby reducing the production of highly destructive oxidants like hypochlorous acid. Furthermore, it modulates signaling pathways (e.g., LTB4, IL-8) that control neutrophil chemotaxis and adherence, limiting their infiltration into tissue. These actions collectively modulate the cellular output of tissue-destructive enzymes and regulate excessive neutrophil-mediated inflammation.

Dosage and Administration Information

How Dapsone is Used: Administration Guidelines

Dapsone is administered via two distinct routesoral for systemic treatment and topical for localized application—with specific regimens defined for usage. Standard administration involves the proper form, dose, and duration for each indication.

Oral Use for Systemic Conditions

The oral tablets are typically taken once daily and may be swallowed with food or milk to help minimize stomach discomfort.

Indication Standard Adult Dosing Principle Duration Pattern
Dermatitis Herpetiformis Initial dose (50 mg once daily) is titrated to a maximum of 300 mg daily, then reduced to the lowest effective maintenance dose (25 mg to 50 mg daily). Often requires long-term continuous administration.
Leprosy (MDT) Fixed dose of 100 mg once daily, used in combination with other anti-leprosy agents. Fixed duration ranging from six months to two years, depending on disease classification.

Topical Use for Localized Conditions

For localized skin application, the gel formulation is applied externally to clean, dry skin. The 7.5% gel is applied once daily, while the 5% gel is applied twice daily. The topical use pattern involves a treatment reassessment after 12 weeks if no clinical improvement is observed.

Population-Specific Adjustments

Specific considerations apply to different groups. For pediatric patients with leprosy, dosing is determined by weight, usually 1.4 mg per kilogram once daily. For older adults, a dose reduction is considered if there is known hepatic impairment. If an oral dose is missed, the practice is to skip the missed dose if it is near the time for the next scheduled dose, avoiding a doubled amount.

Recent Clinical Evidence

Research evidence / Overview of studies for Dapsone

The research base for Dapsone in leprosy is long-standing and historical, relying primarily on observational and historical cohort studies associated with global public health programs. These studies monitored bacteriological status (the clearance of M. leprae) and the frequency of relapse when Dapsone was used as part of a necessary combination regimen. Combination treatment has been the established, official treatment approach for decades, and current research focuses on optimizing these multi-drug regimens.

Evidence for use in Chronic Inflammatory Skin Conditions

Clinical investigation into Dapsone for conditions like Dermatitis Herpetiformis (DH) has been conducted using smaller, prospective evaluations and case series. Studies explored outcomes related to physical discomfort, specifically measuring the change in inflammatory skin lesion counts (papules and vesicles) and the intensity of patient-reported itching. Evidence is limited in that many DH studies are modest in sample size, and long-term outcomes for chronic management are not fully established through randomized evidence, relying instead on observational and clinical experience summaries.

Evidence for use in Preventing Opportunistic Infections (PCP Prophylaxis)

Research examined Dapsone as an alternative preventive strategy for Pneumocystis pneumonia (PCP) in high-risk groups who were unable to tolerate the standard preventive medicine. The research primarily consisted of randomized comparative studies and prospective cohort analyses, monitoring the rate of breakthrough PCP infection and the overall tolerability of different Dapsone regimens. The results apply primarily to highly selected populations, and data for long-term outcomes remain insufficient.

Evidence for use in Topical Acne Vulgaris

The topical gel formulation has been evaluated through multiple large-scale, randomized, double-blind, vehicle-controlled trials (RCTs) in adolescents and adults with moderate to severe facial acne. These large studies reported a statistically defined difference in the achievement of the Investigator's Global Assessment (IGA) success score when comparing the active gel to the inactive vehicle (placebo) after twelve weeks. The follow-up durations were limited in the pivotal efficacy trials, typically concluding after three months, and controlled evidence on sustained effects beyond one year is not fully established.

Frequently Asked Questions (FAQ)

Common questions about Дапсон (FAQ)


Q: What are the main conditions Дапсон is approved to treat?

Дапсон (Dapsone) is approved for treating several conditions, depending on the formulation. The oral tablets are officially indicated for the treatment of leprosy and the chronic skin disorder dermatitis herpetiformis. A topical gel formulation is also approved for treating acne vulgaris.


Q: Does Дапсон cure the underlying condition, or just manage symptoms?

The role of the medicine differs depending on the condition. For leprosy, Dapsone is used as a core component of a combination therapy (MDT) used to suppress or eliminate the bacteria, which can lead to the disease being classified as cured. For dermatitis herpetiformis, however, official regulatory information indicates that Dapsone is primarily used for the long-term management of the severe itching and rash symptoms.


Q: How quickly should I expect to see effects after starting Дапсон?

Official information suggests that the effects can vary depending on what the medicine is being used for. For the inflammatory skin condition dermatitis herpetiformis, patients who respond typically notice a prompt reduction in itching. For localized skin issues like acne, clinical trials are usually designed to show results after 12 weeks of continuous use.


Q: What happens if a dose of Дапсон is missed?

If a dose of oral Dapsone is missed, official patient guidance generally advises taking the dose as soon as it is remembered. However, if it is already very close to the time for the next scheduled dose, regulatory guidance indicates that the missed dose should be skipped entirely to avoid taking a double amount.


Q: Can Дапсон cause tiredness or fatigue?

Yes, official adverse reaction reports list symptoms such as tiredness, unusual weakness, or fatigue. These effects may be associated with the drug's documented effects on the blood.


Q: Is it common to have an upset stomach when first taking Дапсон?

Upset stomach, abdominal pain, and vomiting are documented adverse reactions reported in patients taking the oral tablet formulation. Official administration instructions often note that taking Dapsone with food or milk may help minimize this kind of stomach discomfort.


Q: Are there any specific vitamins or supplements that interact with Дапсон?

Regulatory information indicates that the herbal supplement St. John’s Wort may increase the formation of a Dapsone metabolite that is associated with a risk of hemolysis. Additionally, the label advises caution when combining Dapsone with folic acid antagonists, which are drugs that block folate, due to the potential for increased blood-related risks.


Q: What is the difference between Дапсон and sulfones that treat similar issues?

Dapsone is the core drug in the sulfone chemical class. It is structurally distinct from the sulfonamide class of antibiotics, although both drug classes exert a similar antimicrobial effect by inhibiting the bacterial synthesis of folic acid. Both are often discussed together due to their similar mechanism.


Q: How does Дапсон compare to other medicines used for leprosy?

Dapsone is not typically used alone for leprosy; it is a key medicine within the Multi-Drug Therapy (MDT) regimen recommended by the World Health Organization (WHO). It is used in a fixed combination with other agents, such as rifampicin and clofazimine, which are necessary to manage the disease effectively and prevent drug resistance.


Q: Is it normal to feel dizzy or have headaches on Дапсон?

Yes, regulatory documents list headache, dizziness, and vertigo among the documented side effects associated with the use of oral Dapsone. These are known effects that patients may experience while taking the medication.


Q: Do food or dairy products affect how Дапсон works?

The official administration instructions state that oral Dapsone may be taken with food or milk for the purpose of helping to reduce stomach upset. The topical gel formulation is not noted to have any known interactions with foods or drinks.


Q: Has there been recent research on new uses for Дапсон?

While the focus of official documents remains on Dapsone’s approved uses (leprosy, dermatitis herpetiformis, and acne), regulatory sources also acknowledge research into other applications. This includes studies examining Dapsone as an alternative strategy for preventing Pneumocystis pneumonia (PCP) in high-risk individuals who cannot tolerate the standard preventive medicine.


Q: Are there different forms of Дапсон, like a cream or gel?

Yes, Dapsone is available in two main formats for different uses. It is available as an orally administered tablet for internal treatment that affects the entire body. It is also available as a topical gel formulation for localized application to the skin.


Q: Is Дапсон known to cause skin sensitivity to the sun?

Yes, Dapsone is documented to carry a risk of phototoxicity, which means it can make the skin more sensitive to sunlight. Official guidance recommends planning to avoid unnecessary exposure to sunlight.


Q: Can Дапсон change the color of the skin or eyes?

Regulatory warnings list signs that may involve color changes. These include yellowing of the skin or eyes (jaundice), which can be a sign of liver issues, and a bluish tint to the lips, skin, or fingernails (cyanosis), which can signal methemoglobinemia. Both are signs of potential adverse reactions, and official warnings advise seeking guidance if they occur.


Q: What should I do if I experience a rash while on Дапсон?

Because a rash, particularly if accompanied by fever or flu-like symptoms, may be a signal of a rare but serious adverse reaction like Dapsone Hypersensitivity Syndrome (DHS), official warnings advise that individuals should seek guidance from their healthcare team right away if a rash occurs. The timing of the rash is important, as DHS often manifests a few weeks after starting treatment.


Q: Is it possible to become allergic to Дапсон after using it for a while?

Yes, official warnings describe the potential for a severe, delayed reaction called Dapsone Hypersensitivity Syndrome (DHS). This condition, which is characterized by a rash and multi-organ involvement, typically appears three to six weeks after treatment initiation, not immediately after the first dose.


Q: Does Дапсон affect my ability to drive or operate machinery?

While the regulatory label does not include a direct, universal statement about driving, it does list side effects that could potentially affect mental function or physical coordination. These documented effects include dizziness, vertigo, and blurred vision, and official warnings indicate caution is necessary regarding activities that require alertness.


Q: Are there any dietary restrictions generally recommended while taking Дапсон?

Official labeling for Dapsone notes that for patients using it to manage dermatitis herpetiformis, adopting a strict gluten-free diet is an optional patient management choice. Some official reports note that this diet has allowed certain patients to potentially reduce or eliminate their need for Dapsone.


Q: Why do some people need a lower dose of Дапсон than others?

Dosage differences are common and are based on regulatory guidance. Some people need a lower dose because of the need to titrate (slowly adjust the dose), because they are pediatric patients requiring weight-based dosing, or to reduce the risk of dose-related adverse reactions like hemolysis, particularly in individuals with pre-existing conditions like G6PD deficiency.


Q: Can Дапсон cause a fever or flu-like symptoms?

Yes, fever or flu-like symptoms are noted in official warnings. When these symptoms occur alongside a rash, they are recognized as a potential sign of a severe adverse reaction, such as Dapsone Hypersensitivity Syndrome (DHS), which is a sign of a serious reaction, and official warnings advise seeking guidance.


Q: What is hemolysis, and why is it a concern with Дапсон?

Hemolysis is the term for the process where red blood cells are destroyed. It is the most common dose-related side effect associated with oral Dapsone use, and the regulatory label notes that this can lead to hemolytic anemia (a low red blood cell count). The risk is significantly higher in patients with G6PD deficiency.


Q: Does Дапсон interact with birth control pills?

Some official drug interaction information suggests that oral Dapsone may have a minimal effect on the levels of conjugated estrogens in the body, possibly by altering the natural gut bacteria. While this is noted as a low theoretical risk, official information notes that professional consultation is advised to discuss this potential interaction.


Q: Is Дапсон effective for all types of dermatitis herpetiformis?

Dapsone is broadly indicated for the treatment of dermatitis herpetiformis according to regulatory documents. Studies have examined outcomes where responsive patients experienced a reduction in intense itching and a clearing of skin lesions. The official label does not specifically distinguish its effectiveness between different scientific sub-classifications of the disease.


Q: Does the generic version of Дапсон work the same as the brand name?

Yes, according to government regulatory standards, a generic medication must be shown to be bioequivalent to its brand-name counterpart. This means the generic version contains the same active ingredient and is required to work in the same way, delivering the same amount of active ingredient into the body in the same time frame.


Q: What is the typical length of a treatment course with Дапсон for leprosy?

When used for leprosy, Dapsone is part of a fixed-duration multi-drug therapy (MDT) regimen recommended by the World Health Organization. The treatment course is typically 6 months for Paucibacillary (PB) leprosy and 12 months for Multibacillary (MB) leprosy.


Q: Is it common for Дапсон to be combined with other medicines for treatment?

Yes, it is common and often necessary. For the treatment of leprosy, Dapsone is used as a foundational component in the established multi-drug therapy (MDT). It may also be used in combination with other agents when prescribed for the prevention of certain opportunistic infections in high-risk groups.


Q: Can Дапсон cause numbness or tingling in the hands or feet?

Yes, official patient information for Dapsone notes the documented long-term risk of peripheral neuropathy, which is a nervous system disorder. The symptoms of this condition can manifest as pain, numbness, or tingling sensations in the hands or feet.

How should Дапсон be stored and disposed of?

Storage and Disposal Requirements for Dapsone

Official labeling requires Dapsone to be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, which should be tightly closed and protected from excessive heat, moisture, and light. Dapsone topical gel, in particular, must be protected from freezing and should not be refrigerated.

All Dapsone products must be stored safely out of the sight and reach of children.

For disposal, drug take-back programs are the preferred method for expired or unused medicine. If a take-back option is unavailable, the FDA advises following a procedure that involves mixing the drug with an undesirable substance (e.g., used coffee grounds) in a sealed bag before disposal in household trash, rather than flushing it down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Дапсон found in:

A-Z Index: